Biomarkers and Efficacy: Not (Yet?) a Perfect Union
Scientists at AAIC debated discrepant results, updated a model of the biomarker-efficacy relationship, and debuted the CenTauR scale for tau PET.
ALL NEWS
6448 RESULTS
Sort By:
- Most Recent
- Most Commented
New Alzheimer’s Diagnostic Criteria Remain ‘Research Only’
This clarification comes after geriatricians argued that diagnosing AD in people without symptoms is premature, and the NIH pulled its name.
Clinical Trials on Alzheimer's Disease (CTAD) 2023- 16th
To Recruit for Diverse Alzheimer Trials, Go to the People From St. Louis to Boston, Scientists Grapple with Ethnoracial Divide in AD Biomarkers Treat Before ‘Aβ Bothers Tau,’ Scientists Say at CTAD Moving Forward: RNA-Targeted Attempts at Taking Down Tau,
Putting Palmitate on Synaptotagmin-11 Stymies α-Synuclein Tetramers
The fatty acid shields Syt11 from degradation. With more of it around, α-synuclein monomers cling to membranes.
Polygenic Scores Point to Microglia, Astrocytes in Alzheimer's Pathogenesis
Cell-type-specific polygenic risk scores single out microglia as influencers of Aβ and tau pathology, as well as cognitive decline.
Holloway Summit 2023: FTD Biomarkers
Second Holloway Summit Showcases Intense Search for FTD Biomarkers At Holloway Summit, FTD Imaging Shows New Vista To enable clinical trials in frontotemporal dementia, scientists need biomarkers that distinguish its several underlying pathologies. At a r
New Atlas Charts Mouse Brain in Exquisite Detail
Researchers wrangled gene expression, epigenetic, and spatial transcriptomic data on 32 million brain cells into the most detailed picture of the mouse brain yet.
Synuclein Assay Passes the Sniff Test—What of Other Seeds?
Analysis of cerebrospinal fluid from the Parkinson’s Progression Markers Initiative identifies PD with high sensitivity and specificity.
Copper Mountain: Death and Trophin Receptors—New Insight, New Drugs?
Death and taxes are reputedly inevitable, though death and receptors may be more interesting to Alzforum readers...
Second Holloway Summit Showcases Intense Search for FTD Biomarkers
Scientists have identified potential fluid and imaging markers that could discriminate between the two main proteopathies of FTD, tau and TDP-43.
2023—A Bumper Year for the Treatment and Science of Alzheimer's
Last summer saw a first: the traditional approval of a disease-modifying Alzheimer's therapy. Solid progress on biomarkers, and a flourishing of basic research, made for a good year.
Sit Less, Move More to Induce Irisin and Stave Off Dementia
In people over 60, sitting for 12 hours per day increased dementia risk. An exercise-induced hormone, irisin, protects via astrocytes, at least in vitro.
Two New p-Tau217 Blood Tests Join a Crowded Field
C2N’s PrecivityAD2 and ALZpath Inc.’s p-tau217 immunoassay identify people with AD with good accuracy.
Paper Alert: p-Tau217 Blood Test Predicts Plaques, Tangles Over Time
ALZpath’s assay detected an annual rise in plasma phospho-tau217 in amyloid-positive people, with the steepest increase in those who also have tangles.
Lecanemab Sweeps Up Toxic Aβ Protofibrils, Catches Eyes of Trialists
In a comparison with aducanumab and gantenerumab, lecanemab mopped up protofibrils most efficiently; the antibody has been chosen for DIAN-TU and AHEAD 3-45 trials.
Current Filters
- Date Range : All x